Picture of Bionik Laboratories logo

BNKL Bionik Laboratories Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapNeutral

Annual income statement for Bionik Laboratories, fiscal year end - March 31st, USD millions except per share, conversion factor applied.

2018
March 31st
2019
March 31st
C2020
March 31st
2021
March 31st
2022
March 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue0.9873.252.151.191.27
Cost of Revenue
Gross Profit0.5851.621.260.9240.953
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses10.812.727.214.511.2
Operating Profit-9.77-9.49-25.1-13.3-9.97
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-14.6-10.6-25-13.6-10.4
Net Income After Taxes-14.6-10.6-25-13.6-10.4
Net Income Before Extraordinary Items
Net Income-14.6-10.6-25-13.6-10.4
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-14.6-10.6-25-13.6-10.4
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-21.7-4.47-2.49-1.26-0.891

Or unlock with your email

Or unlock with your email